termsTerm

PSA50 / PSA90 response

PSA50 is the share of patients whose PSA falls by at least half on treatment, and PSA90 the share whose PSA falls by 90%.

Standard early-efficacy read-out in mCRPC trials (VISION PSA50 46%; TheraP 66% vs 37%). Correlates with but does not replace rPFS/OS; PSA90 futility ended masofaniten's phase 2.

Endpoints: what this kind of term is about · animated schematic, not to scale

Connected

4top

Pages like this

not linked directly; found by shared links

Target
STEAP1
Shares Xaluritamig, Prostate cancer.
Trial
XALute
Shares Xaluritamig, Prostate cancer.
Term
Biochemical recurrence (BCR)
Shares PSA (prostate-specific antigen), Prostate cancer.
Product
Cabazitaxel
Shares TheraP (ANZUP 1603), Prostate cancer.
Collection
Prostate Cancer Foundation (PCF)
Shares PSA (prostate-specific antigen), Prostate cancer.
Person
Michael Hofman
Shares TheraP (ANZUP 1603), Prostate cancer.
Institution
ANZUP Cancer Trials Group
Shares TheraP (ANZUP 1603), Prostate cancer.
Company
Amgen
Shares Xaluritamig, Prostate cancer.

PSA50 / PSA90 response

Connected

Pages like this

cancers

drugs

terms

trials